Compare Motorola Solutions Inc (MSI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Motorola Solutions Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Motorola Solutions Inc trades at $446.82 (market cap $74.20B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Motorola Solutions Inc pays a 1.08% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Motorola Solutions Inc for 100 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| MSI | VRTX | |
|---|---|---|
Market Cap | $74.20B | $128.16B |
Volume | 720,826 | 806,603 |
Sector | Technology | Health |
52-Week High | $491.24 | $557.96 |
52-Week Low | $363.83 | $407.37 |
Typical Hold Time | 100 Days | 120 Days |
Enterprise Value | $83.10B | $122.29B |
Dividend Yield | 1.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Motorola Solutions (MSI) trades at $447.12, down 2.02% today, amid a bearish technical signal. The company maintains strong fundamentals with Q2 2026 EPS of $4.41 beating expectations and record backlog of $15.6 billion. Recent acquisitions including D-Fend Solutions for $1.5 billion expand its counter-drone security capabilities, while new contracts with Louisiana and the US Navy demonstrate ongoing demand.
MSI presents a compelling growth story with robust earnings momentum and strategic expansion, though elevated valuation ratios and significant capital expenditures pose risks. Analyst consensus remains bullish with a $525.86 price target, representing 17.6% upside potential from current levels.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
